AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25298016 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MIC)
Number of subjects: 89
Study 25298016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 89
Study 22118062 — intervention group
Group type: EXPERIMENTAL
Intervention: PEER intervention
Number of subjects: 60
Study 22118062 — intervention group
Group type: COMPARATOR
Intervention: CHILD intervention
Number of subjects: 60
Study 22118062 — intervention group
Group type: COMPARATOR
Intervention: Both PEER and CHILD interventions
Number of subjects: 60
Study 19542866 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC 600 mg/300 mg with lopinavir/ritonavir 800 mg/200 mg
Number of subjects: 688
Study 19542866 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with lopinavir/ritonavir 800 mg/200 mg
Number of subjects: 688
Study 19542866 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC
Number of subjects: 688
Study 19542866 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 688
Study 17305685 — intervention group
Group type: EXPERIMENTAL
Intervention: First impression assessment based on pain drawing (PD)
Number of subjects: 50
Study 17305685 — intervention group
Group type: COMPARATOR
Intervention: Final assessment based on clinical examination
Number of subjects: 50
Study 15147545 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuprolide and chlormadinone acetate) for 3 months followed by radical prostatectomy and subsequent adjuvant endocrine therapy (leuprolide alone)
Number of subjects: 176
Study 15147545 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by 3-month androgen deprivation (leuprolide and chlormadinone acetate) and subsequent adjuvant endocrine therapy (leuprolide alone)
Number of subjects: 176
Study 15147545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation
Number of subjects: 176
Study 15147545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation in subpopulation with PSA < 35.6 ng/mL and clinical stage B or C cancers
Number of subjects: 176
Study 11120904 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (1 mg/kg/day for three months, then 10 mg/day for three months)
Number of subjects: 24
Study 11120904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10092565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (n = 56)
Number of subjects: 133
Study 10092565 — intervention group
Group type: COMPARATOR
Intervention: Reassured following angiography
Number of subjects: 133
Study 10092565 — intervention group
Group type: COMPARATOR
Intervention: Reassured without angiography
Number of subjects: 133
Study 8527061 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-representation scores in middle-aged adults
Number of subjects: 149
Study 8527061 — intervention group
Group type: COMPARATOR
Intervention: Self-representation scores in preadolescents and older adults
Number of subjects: 149
Study 8527061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and personality variables
Number of subjects: 149
Study 8527061 — intervention group
Group type: EXPERIMENTAL
Intervention: Age segments (younger vs older)
Number of subjects: 149
Study 2180866 — intervention group
Group type: EXPERIMENTAL
Intervention: 67.2 Gy
Number of subjects: 237
Study 2180866 — intervention group
Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 237
Study 2180866 — intervention group
Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 237
Study 7407516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate while not smoking
Number of subjects: 10
Study 7407516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate while smoking
Number of subjects: 10
Study 7407516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate and propranolol (380 mg/day) while not smoking
Number of subjects: 10
Study 7407516 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate and propranolol while smoking
Number of subjects: 10
Study 29148144 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1645
Study 29148144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study 27456328 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention involving GPs and HCAs conducting checklist-based interviews and medication reconciliation with the aid of a CDSS.
Number of subjects: 100
Study 27456328 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study 25250737 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief treatment (CGT) - 16 sessions delivered approximately weekly (n=74)
Number of subjects: 151
Study 25250737 — intervention group
Group type: COMPARATOR
Intervention: Grief-focused interpersonal psychotherapy (IPT) - 16 sessions delivered approximately weekly (n=77)
Number of subjects: 151
Study 22463965 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG technician (ECG-T)
Number of subjects: 354
Study 22463965 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 354
Study 22463965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing staff assessment of intervention
Number of subjects: 354
Study 22463965 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-to-EP time
Number of subjects: 354
Study 22463965 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis time
Number of subjects: 354
Study 20394610 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape (TOT) - ARIS for the 'outside-in' route
Number of subjects: 341
Study 20394610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape-obturator (TVT) - O for the 'inside-out' route
Number of subjects: 341
Study 20394610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 341
Study 18545059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3-12 mg/day
Number of subjects: 198
Study 18545059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 18545059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 198
Study 15917682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous injection
Number of subjects: 20
Study 15917682 — intervention group
Group type: COMPARATOR
Intervention: Infiltration injection
Number of subjects: 20
Study 12692056 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b, 3 million units (MU), three times a week, and oral ribavirin (1000 mg/day)
Number of subjects: 114
Study 12692056 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 3 MU daily for the first four weeks and subsequently 3 MU three times a week, and ribavirin as in regimen A
Number of subjects: 114
Study 12692056 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin as in regimen B, plus oral amantadine hydrochloride (200 mg/day)
Number of subjects: 114
Study 10726917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) coinfused with insulin from 120 to 240 minutes
Number of subjects: 19
Study 10726917 — intervention group
Group type: COMPARATOR
Intervention: Control (insulin infusion using euglycemic clamp protocol for 240 minutes at a rate of 40 mU/m2/min for young and 34 mU/m2/min for old)
Number of subjects: 19
Study 10726917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) coinfused with insulin
Number of subjects: 19
Study 10726917 — intervention group
Group type: COMPARATOR
Intervention: Control (insulin infusion)
Number of subjects: 19
Study 8797404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms)
Number of subjects: 25
Study 8797404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1335641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14
Number of subjects: 0
Study 1335641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 28
Number of subjects: 0
Study 1335641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 360 ELISA units (El.U) on days 0 and 28
Number of subjects: 0
Study 1335641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine, strain HM175, 720 ELISA units (El.U) on days 0 and 14 (abbreviated schedule)
Number of subjects: 0
Study 6206796 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin Nocardia rubra cell wall skeleton (N-CWS)
Number of subjects: 55
Study 6206796 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (control group)
Number of subjects: 55
Study 6206796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial instillation of anti-cancer drugs (Carbazilquinone, Mitomycin-C, ACNU) with pericardial drainage
Number of subjects: 55
Study 2417474 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (4 treatment tracks)
Number of subjects: 0
Study 2417474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 treatment track)
Number of subjects: 0
Study 2417474 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment tracks (active and placebo)
Number of subjects: 0
Study 30151212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 50 and 75 mg single dose
Number of subjects: 125
Study 30151212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg
Number of subjects: 125
Study 30151212 — intervention group
Group type: COMPARATOR
Intervention: Mirogabalin (various doses)
Number of subjects: 125
Study 26996385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib (60 mg daily)
Number of subjects: 45
Study 26996385 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone (50 mg once daily)
Number of subjects: 45
Study 26996385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Veliparib
Number of subjects: 45
Study 24102899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=32) attended eight 2-hour group sessions once a week.
Number of subjects: 63
Study 24102899 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31) did not receive the intervention.
Number of subjects: 63
Study 22978196 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual control training with a visual constraint (shooting with a screen blocking the basket)
Number of subjects: 0
Study 19726418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (mean dose 118 mg)
Number of subjects: 29
Study 19726418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19726418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 29
Study 19323001 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise participation
Number of subjects: 12
Study 19323001 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 12
Study 15892594 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin 40mg once daily
Number of subjects: 0
Study 12699438 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703 (3 mg/kg first dose, 1.5 mg/kg/day for 6 days)
Number of subjects: 97
Study 12699438 — intervention group
Group type: EXPERIMENTAL
Intervention: NN703
Number of subjects: 97
Study 12699438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 12699438 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 micro g/kg)
Number of subjects: 97
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose PRP-T Hib vaccine
Number of subjects: 600
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose PRP-T Hib vaccine
Number of subjects: 600
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third-dose PRP-T Hib vaccine
Number of subjects: 600
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600
Study 11220764 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third-dose PRP-T Hib vaccine combined with DTP
Number of subjects: 600
Study 8837189 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 210
Study 8837189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg droperidol
Number of subjects: 210
Study 8837189 — intervention group
Group type: COMPARATOR
Intervention: 2 mg morphine
Number of subjects: 210
Study 8837189 — intervention group
Group type: COMPARATOR
Intervention: 4 mg morphine
Number of subjects: 210
Study 1486261 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethylxanthine (800 mg in caffeinated coffee)
Number of subjects: 20
Study 1486261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, went to sleep at 2300 hours)
Number of subjects: 20
Study 2981491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2), 1 mg/ml
Number of subjects: 18
Study 2981491 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-oxo-PGF1 alpha, 1 mg/ml
Number of subjects: 18
Study 2981491 — intervention group
Group type: COMPARATOR
Intervention: Glycine vehicle
Number of subjects: 18
Study 31468137 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID for 7 days in a 21-day cycle with carboplatin/paclitaxel
Number of subjects: 168
Study 31468137 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID
Number of subjects: 168
Study 30499482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity pulsed magnetic field therapy
Number of subjects: 117
Study 30499482 — intervention group
Group type: COMPARATOR
Intervention: Medicamentous therapy with hymecromone and 'Sernovodskaya' mineral water
Number of subjects: 117
Study 30499482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including high-intensity pulsed magnetic field, mineral water, and pharmacotherapy
Number of subjects: 117
Study 25645270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined verbal and numerical risk expressions (e.g. 'common: may affect up to 1 in 10 people')
Number of subjects: 339
Study 25645270 — intervention group
Group type: COMPARATOR
Intervention: Numerical frequency bands (e.g. 'may affect up to 1 in 10 people')
Number of subjects: 339
Study 25645270 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk qualifier verb manipulation ('may affect' or 'will affect')
Number of subjects: 339
Study 24488143 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (ado-trastuzumab emtansine)
Number of subjects: 0
Study 24488143 — intervention group
Group type: COMPARATOR
Intervention: Active control (lapatinib plus capecitabine)
Number of subjects: 0
Study 22147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic MCT at 50 μA for 35 hours
Number of subjects: 62
Study 22147671 — intervention group
Group type: COMPARATOR
Intervention: Monophasic MCT at 500 μA for 35 hours
Number of subjects: 62
Study 22147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic MCT at approximately 25 μA for 15 hours
Number of subjects: 62
Study 22147671 — intervention group
Group type: COMPARATOR
Intervention: Monophasic MCT at approximately 25 μA for 189 hours
Number of subjects: 62
Study 22147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of both trials
Number of subjects: 62
Study 20394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning program for pediatric asthma (Web- or CD-ROM-based multimedia learning modules and two teleconference calls)
Number of subjects: 24
Study 20394510 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning program for pediatric asthma
Number of subjects: 24
Study 20394510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 17912794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing in addition to routine INR monitoring
Number of subjects: 0
Study 17912794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Number of subjects: 0
Study 17912794 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 0
Study 16365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening intervention
Number of subjects: 1413
Study 12048334 — intervention group
Group type: EXPERIMENTAL
Intervention: With handgrip (WG)
Number of subjects: 9
Study 12048334 — intervention group
Group type: COMPARATOR
Intervention: Without handgrip (WOHG)
Number of subjects: 9
Study 11073849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 38
Study 11073849 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 38
Study 8806974 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 24
Study 8806974 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 24
Study 8806974 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24
Study 1623913 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (dosage not specified)
Number of subjects: 0
Study 1623913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6475710 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 115
Study 6475710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 30954400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear myocardial perfusion imaging (MPI)
Number of subjects: 8889
Study 30954400 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 8889
Study 30954400 — intervention group
Group type: COMPARATOR
Intervention: Stress echocardiogram
Number of subjects: 8889
Study 30954400 — intervention group
Group type: COMPARATOR
Intervention: Stress electrocardiogram
Number of subjects: 8889
Study 30954400 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography (Cath) following MPI
Number of subjects: 8889
Study 30954400 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography (Cath) following CTA
Number of subjects: 8889
Study 30954400 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 8889
Study 30043965 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Training for Effective Parenting (STEP)
Number of subjects: 17
Study 28826068 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at Home‐Men's Program (SAH‐M)
Number of subjects: 135
Study 28826068 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 135
Study 25462201 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TAP block with 30 cc of 0.25% bupivacaine with 3 mcg/mL epinephrine
Number of subjects: 64
Study 25462201 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 64
Study 25462201 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral TAP block
Number of subjects: 64
Study 23132642 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral neutral and acidic oligosaccharide supplementation
Number of subjects: 113
Study 23132642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 21510271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2T) administered seven days after surgery (n = 8) for 60 minutes at 2.5 ATA for five consecutive days after T2 stage.
Number of subjects: 16
Study 21510271 — intervention group
Group type: COMPARATOR
Intervention: Control group without HBO2T (n = 8).
Number of subjects: 16
Study 18155284 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass allergen tablet immunotherapy (GRAZAX)
Number of subjects: 351
Study 18155284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 16582844 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 80
Study 16582844 — intervention group
Group type: COMPARATOR
Intervention: GP care
Number of subjects: 80
Study 14519610 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 0
Study 14519610 — intervention group
Group type: COMPARATOR
Intervention: Offering psychological intervention
Number of subjects: 0
Study 10903015 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate hyperventilation (group I)
Number of subjects: 30
Study 10903015 — intervention group
Group type: COMPARATOR
Intervention: Delayed hyperventilation (group D)
Number of subjects: 30
Study 9091940 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 1092
Study 9091940 — intervention group
Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 1092
Study 8452166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7-14 days
Number of subjects: 80
Study 8452166 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 200 mg twice daily for 7-14 days
Number of subjects: 80
Study 3533419 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol/dl‐norgestrel combination
Number of subjects: 27
Study 3533419 — intervention group
Group type: EXPERIMENTAL
Intervention: danazol
Number of subjects: 27
Study 30487248 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD gene therapy delivered into the subthalamic nucleus (STN)
Number of subjects: 0
Study 30487248 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 27519144 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (300mg)
Number of subjects: 93
Study 27519144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 27519144 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 93
Study 24698572 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Reduction and Internal Fixation (CRIF)
Number of subjects: 285
Study 24698572 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 285
Study 23737536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-dose DSA program with modified acquisition parameters
Number of subjects: 20
Study 23737536 — intervention group
Group type: COMPARATOR
Intervention: Reference DSA program
Number of subjects: 20